AstraZeneca Spies Success For Antibody To Prevent COVID-19 Infection In Vulnerable

Could Be First With Pre-Exposure Authorization

While it is likely to be fourth to market, AstraZeneca’s long-acting antibody combination could help the US battle SARS-CoV-2 in vaccine-skeptical states, data from study suggests.

AstraZeneca
AstraZeneca's antibody combination, if authorized, will be fourth to market, but could prevent infection in vulnerable populations in whom vaccines are not fully effective, or in the unvaccinated.

AstraZeneca’s long-acting coronavirus antibody combination AZD7442 has scored its first trial success, reducing the risk of developing symptomatic COVID-19 by 77% compared with placebo.

The positive results come from the PROVENT Phase III trial of the antibody combination as a pre-exposure prophylaxis – achieving...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

Test

Sponsored by :

Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.